These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26306453)

  • 1. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.
    Caocci G; Martino B; Greco M; Abruzzese E; Trawinska MM; Lai S; Ragatzu P; Galimberti S; Baratè C; Mulas O; Labate C; Littera R; Carcassi C; Gambacorti Passerini C; La Nasa G
    Exp Hematol; 2015 Dec; 43(12):1015-1018.e1. PubMed ID: 26306453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic Polymorphisms of
    Ureshino H; Shindo T; Kojima H; Kusunoki Y; Miyazaki Y; Tanaka H; Saji H; Kawaguchi A; Kimura S
    Cancer Immunol Res; 2018 Jun; 6(6):745-754. PubMed ID: 29695383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
    La Nasa G; Caocci G; Littera R; Atzeni S; Vacca A; Mulas O; Langiu M; Greco M; Orrù S; Orrù N; Floris A; Carcassi C
    Exp Hematol; 2013 May; 41(5):424-31. PubMed ID: 23380384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic myeloid leukemia and NK cell immunity].
    Ureshino H; Shindo T; Tanaka H; Kimura S
    Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
    Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.
    Izumi K; Shindo T; Ngo HT; Nakayama-Hosoya K; Akahane K; Tamai M; Nguyen TTT; Kawana-Tachikawa A; Inukai T; Takaori-Kondo A
    Immunohorizons; 2021 Aug; 5(8):687-702. PubMed ID: 34433624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic polymorphisms of
    Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
    Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
    Kröger N; Binder T; Zabelina T; Wolschke C; Schieder H; Renges H; Ayuk F; Dahlke J; Eiermann T; Zander A
    Transplantation; 2006 Oct; 82(8):1024-30. PubMed ID: 17060849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
    Ureshino H; Shindo T; Sano H; Kubota Y; Ando T; Kidoguchi K; Kusaba K; Itamura H; Kojima H; Kusunoki Y; Miyazaki Y; Kojima K; Tanaka H; Saji H; Oshima K; Kimura S
    Int J Hematol; 2020 May; 111(5):733-738. PubMed ID: 31873846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M; Yamamoto T; Sakamoto Y
    Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
    Dumas PY; Bérard E; Bréal C; Dulucq S; Réa D; Nicolini F; Forcade E; Dufossée M; Pasquet JM; Turcq B; Bidet A; Milpied N; Déchanet-Merville J; Lafarge X; Etienne G; Mahon FX;
    Cancer Med; 2019 Sep; 8(11):4976-4985. PubMed ID: 31287239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
    Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
    Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killer cell immunoglobulin-like receptors in Thai patients with leukemia and diffuse large B-cell lymphoma.
    Vejbaesya S; Sae-Tam P; Khuhapinant A; Srinak D
    Hum Immunol; 2014 Jul; 75(7):673-6. PubMed ID: 24755352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
    van der Meer A; Schaap NP; Schattenberg AV; van Cranenbroek B; Tijssen HJ; Joosten I
    Mol Immunol; 2008 Aug; 45(13):3631-8. PubMed ID: 18555529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
    Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
    J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.